• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Microbiologics Expands Virology Services

    ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies

    Executive Moves: Novavax

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion

    Catalent Biologics Completes Madison Expansion
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion

    Ensuring Pharma Manufacturing Quality

    Exploring ICP-MS expertise at Almac

    Catalent Biologics Completes Madison Expansion

    Ascendia Pharmaceuticals Poised for Expansion
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success

    Enteris BioPharma: Custom Solutions – From Bench to Market

    The Benefits of Outsourcing Cold Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Microbiologics Expands Virology Services

    ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion

    Exploring ICP-MS expertise at Almac

    Catalent Biologics Completes Madison Expansion
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Ensuring Pharma Manufacturing Quality

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Emergent BioSolutions

    PCI Pharma Services

    Baxter BioPharma Solutions

    Reed-Lane

    Adare Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Almac Group

    Baxter BioPharma Solutions

    Reed-Lane

    Adare Pharma Solutions

    Aphena Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Top Companies Report

    03 Roche

    ...

    03	Roche
    Related CONTENT
    • Legacy Pharma Solutions
    • Mogene
    • Softweb Solutions
    • Convelo, Genentech to Collaborate on Remyelinating Therapies
    • Pistoia Alliance, backed by Roche, AZ and Bayer, to Introduce FAIR Project
    07.15.19
    Headquarters: Basel, Switzerland
    twitter.com/Roche
    www.roche.com



    Headcount: 94,442 
    Total Revenues:  $57,734  (+7%)
    Pharma Revenues:  $44,654  (+5%)
    Net Income:  $11,035  (+23%)
    R&D:  $12,281  (+6%)

    TOP SELLING DRUGS  
    Drug Indication 2018 Sales (+/-%)
    MabThera/Rituxan rheumatoid arthritis $6,905 -8%
    Herceptin cancer $7,140 0%
    Avastin breast cancer $7,004 3%
    Perjeta breast cancer $2,836 27%
    Ocrevus Relapsing-Remitting MS (RRMS) $2,406 173%
    Xolair asthma $1,986 12%
    Actemra/
    RoActemra
    rheumatoid arthritis $1,847 12%
    Lucentis macular degeneraton $1,697 18%
    Activase/TNKase myocardial infarction $1,313 6%
    Esbriet Pulmonary fibrosis, idiopathic $1,054 19%


    Roche’s pharma sales grew 5% to $44.6 billion in 2018. Key growth drivers were the new multiple sclerosis medicine Ocrevus and cancer medicines Perjeta, Tecentriq, Alecensa as well as the new haemophilia medicine Hemlibra. With sales of $2.4 billion in its first full year on key markets, Ocrevus is the most successful new product launch in Roche’s history.

    On the regulatory front, the Swiss pharma giant received several major approvals during the year. In the fourth quarter, FDA gave the green light to Tecentriq in combination with Avastin for a specific form of lung cancer. The regulator also granted accelerated approval for leukaemia drug Venclexta, and approved Xofluza, which is used to treat the flu.

    At the end of the year it was announced that Roche’s CEO, Daniel O’Day, was stepping down from the helm after being with the company for more than 30 years in various roles. William Anderson succeeded him as the new chief executive at the start of 2019, having previously served as CEO of Genentech since 2017.

    Oncology acquisitions
    In 2018, Roche concluded several oncology-focused transactions to advance its personalized healthcare strategy with three U.S.-based acquisitions.

    Three years after buying a majority stake in Foundation Medicine for more than $1 billion as part of a research and development collaboration, Roche acquired the rest of the company in a $2.4 billion follow-on deal for the business, which selects cancer treatments for patients based on their genetic profile.

    The deal came on the heels of Roche’s $1.9 billion acquisition of oncology-focused electronic health record (EHR) software developer Flatiron Health. They make oncology-specific EHR systems, most notably an information exchange platform which allows researchers to access and learn from patient records. The company’s message is that large amounts of data could be used to speed up and, in some cases, replace certain clinical trials where patients are randomly assigned to a specific treatment.

    Roche also entered an agreement to acquire Ignyta, a U.S. based pharmaceutical company focused on developing cancer therapies, for $1.7 billion. The acquisition expands Roche’s oncology portfolio globally. Ignyta will continue its operations in San Diego and will be responsible for the ongoing study of entrectinib, its most advanced cancer drug being studied in a range of solid tumor types. The company also has a portfolio of drugs in early stage of development that use gene therapy to kill the underlying diseases that drive cancer tumor growth. Ignyta employs an integrated “Rx/Dx” approach that combines precision medicines (Rx) and in-house molecular diagnostics (Dx) to both identify and target hard-to-treat cancers in hard-to-find patients.

    Research collaborations
    Roche entered several cancer research collaborations during the year. In the cellular therapy arena, it formed a deal with SQZ Biotechnologies to jointly develop and commercialize certain products based on antigen presenting cells (APCs) created by the SQZ platform for the treatment of oncology indications. The companies are also expanding a 2015 collaboration to jointly develop therapeutics derived from peripheral blood mononuclear cells (PBMCs).

    With Kymab Group, Roche entered a clinical trial agreement, under which it will provide its PD-L1 blocking antibody atezolizumab for use in combination in Kymab’s upcoming Phase I-II clinical studies combining its lead investigational anti-ICOS antibody therapy KY1044 in patients with advanced solid cancers. Kymab will be responsible for conducting the clinical trials, and both companies will share data from the trials. Kymab continues to retain all commercial rights to KY1044.

    Syapse and Roche entered into a multi-year strategic collaboration to help make precision medicine available to more cancer patients. Syapse and Roche will work jointly to develop software products and analytics solutions to provide the tools and insights healthcare providers need to practice precision medicine at scale, with the goal of improving patient outcomes. The companies will initially focus on four product programs: real-world evidence, so that physicians can make better care decisions; better understanding the health economics impact and patient outcomes of precision medicine; advancing electronic patient-reported outcomes to understand precision medicine’s effect on health-related quality of life; and accelerating clinical trial enrollment by matching patients to precision trials at the point of care.

    Roche entered research deals in therapeutic areas other than cancer as well during the year. In diabetes, it partnered with Zealand Pharma for the Phase 3 trials with dasiglucagon for treatment of congenital hyperinsulinism (CHI). Zealand is responsible for conducting the Phase 3 trials, while Roche Diabetes Care provides its Accu-Chek Combo pump system for this study.

    Icagen entered into a license and collaboration agreement with Roche to develop and commercialize small molecule ion channel modulators for the treatment of neurological disorders. The program incorporates Icagen’s platform for ion channels and is directed at a specific novel ion channel target expressed in neurons.

    With BioMed X, Roche entered a research collaboration in the field of immunology. BioMed X launched a global call for applications to establish a new biomedical research group in Heidelberg, Germany with the goal of developing novel approaches for the treatment of several immune-mediated diseases. 
    Related Searches
    • cancer
    • software
    • ceo
    • real-world evidence
    Suggested For You
    Legacy Pharma Solutions Legacy Pharma Solutions
    Mogene Mogene
    Softweb Solutions Softweb Solutions
    Convelo, Genentech to Collaborate on Remyelinating Therapies Convelo, Genentech to Collaborate on Remyelinating Therapies
    Pistoia Alliance, backed by Roche, AZ and Bayer, to Introduce FAIR Project Pistoia Alliance, backed by Roche, AZ and Bayer, to Introduce FAIR Project
    Skyhawk, Genentech Enter Exclusive Multi-target RNA Alliance Skyhawk, Genentech Enter Exclusive Multi-target RNA Alliance
    Top 25 Pharma and Biopharma Companies Top 25 Pharma and Biopharma Companies
    The Top Companies Report The Top Companies Report
    FLAMMA Acquires Teva’s Philadelphia cGMP Facility FLAMMA Acquires Teva’s Philadelphia cGMP Facility
    Celldex Therapeutics Appoints CMO Celldex Therapeutics Appoints CMO
    Japan First to Approve Roche’s Rozlytrek Japan First to Approve Roche’s Rozlytrek
    FDA Approves Roche FDA Approves Roche's Kadcyla for HER2-Positive Early Breast Cancer
    The Orphan Promise The Orphan Promise
    FDA Approves Roche’s Venclexta for CLL FDA Approves Roche’s Venclexta for CLL
    The Manufacturing Revolution In Medicine The Manufacturing Revolution In Medicine

    Related Top Companies Report

    • 25 CSL Behring

      25 CSL Behring

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.20.20

    • 22 Astellas

      22 Astellas

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.20.20

    • 21 Biogen

      21 Biogen

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.20.20


    • 12 Amgen

      12 Amgen

      ...
      Tim Wright, Editor, Contract Pharma 07.20.20

    • 13 Gilead Sciences

      13 Gilead Sciences

      ...
      Kristin Brooks, Managing Editor 07.15.20

    • 10 Bristol-Myers Squibb

      10 Bristol-Myers Squibb

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.15.20


    • 03 Novartis

      03 Novartis

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 02 Roche

      02 Roche

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 09 Takeda

      09 Takeda

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20


    • 01 Pfizer, Inc.

      01 Pfizer, Inc.

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • The 2020 Top 25 Pharma and Biopharma Companies

      The 2020 Top 25 Pharma and Biopharma Companies

      Top 25 Pharma and Biopharma Companies (Based on 2019 Pharma/Biopharma Sales, in $U.S. Millions)
      Contract Pharma Staff 07.15.20

    • 08 GlaxoSmithKline

      08 GlaxoSmithKline

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20


    • 07 AbbVie

      07 AbbVie

      ...
      Kristin Brooks , Managing Editor, Contract Pharma 07.15.20

    • 06 Sanofi

      06 Sanofi

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 05 Merck

      05 Merck

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    Trending
    • Astellas, Affinivax In Global MAPS Vax Pact
    • Ascendia Pharmaceuticals Poised For Expansion
    • Sanofi To Build New $700M Flu Vaccine Facility In Canada
    • Catalent Biologics Completes Madison Expansion
    • ANI Acquires Branded Products Portfolio From Sandoz
    Breaking News
    • Microbiologics Expands Virology Services
    • ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies
    • Executive Moves: Novavax
    • Albumedix Completes Commercial-Scale Mfg. Facility Expansion
    • Catalent Biologics Completes Madison Expansion
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Four-Week Fish Oil Regimen Showed Significant Muscular Damage Protection in Recent Study
    Review Covers Role of Vitamin K2 in the ‘Calcium Paradox’
    KD Pharma Acquires Rohner AG Manufacturing Assets
    Coatings World

    Latest Breaking News From Coatings World

    Jebsen & Jessen, Innospec Sign Distribution Agreement
    Shepherd Color Unveils Bismuth Vanadate Yellow Pigment
    HMG Paints Reports Positive Feedback on Contract Matt Emulsion
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    BioSig Launches Software Update for PURE EP Electrophysiology Platform
    Katena Acquires Ophthalmic Surgical Instrument Maker ASICO
    Vicarious Surgical Appoints CFO and Chief Legal Officer
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Microbiologics Expands Virology Services
    ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies
    Executive Moves: Novavax
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Cosmoprof Worldwide Bologna Postpones 2021 Show
    Native Launches Broad Spectrum SPF 30 Mineral Sunscreens
    Revieve Launches Skin Coach
    Happi

    Latest Breaking News From Happi

    BASF Increases Price of Kaolin
    Kao Launches Online Beauty Store in Europe
    Neutrogena Takes Action on Skin Health Disparities
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Maxcess updates user interface for Fife guiding Sensor
    Bobst announces virtual packaging industry event
    Edale appoints agent in Poland
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    PFNonwovens Adding New Capabilities in Znojmo
    Russ Torres Named Group President of Kimberly-Clark North America
    Aries Face Masks Meet ASTM Standards
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Biogennix Rolls Out Agilon Strip Bone Graft
    Global Bone Tumor Ablation Devices Market to Top $111 Million by 2027
    GreenBone Ortho Closes 10 Million Euros Series B Funding Round
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Virtual ASMC 2021 Spotlights Advanced Semiconductor Manufacturing Excellence
    European Commission's Innovation Radar Acknowledges 3 ARMOR Innovations
    SUPERSMART Wins 'Best Publicly Funded Project Demonstrator' in 2021 OE-A Competition

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login